CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Crispr Therapeutics AG, with a price target o...

Bank of America Securities Remains a Buy on Crispr Therapeutics AG (CRSP)

Cathie Wood’s ARK Invest sold 3,578 shares of Meta Platforms ($META) on March 25, across three of its actively managed ETFs. The sale, worth nearly...

Cathie Wood’s ARK Invest Dumps $2.1M Worth of META Shares; Stock Sinks

IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors

Crispr Therapeutics AG ( ($CRSP) ) just unveiled an announcement. On March 16, 2026, CRISPR Therapeutics AG completed a $600 million private offeri...

Crispr Therapeutics Completes $600 Million Convertible Notes Offering

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio moves on Thursday, March 12, according to the firm’s daily tra...

Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS

Healthcare is diverse sector of the economy. 


	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRSP	$51.50	+3.62%	1.33M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRSP	$51.50	+3.6%	1.33M
3
4
5
6

CRSP

CRSP

No Data Available

Get CRISPR Therapeutics AG Data in Excel

Get CRISPR Therapeutics AG Data in Excel